Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association | oneGRAVESvoice
Global Search
Global Search

Trusted Resources: Evidence & Education

Scientific literature and patient education texts

Back to Evidence & Education / Guides & Guidelines

Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association

key information

source: European Thyroid Journal

authors: Henry B Burch,corresponding author1,2,3,* Petros Perros,4,* Tomasz Bednarczuk,5 David S Cooper,6 Peter J Dolman,7 Angela M Leung,8 Ilse Mombaerts,9 Mario Salvi,10 and Marius N Stan11

summary/abstract:

Thyroid eye disease (TED) remains challenging for clinicians to evaluate and manage. Novel therapies have recently emerged, and their specific roles are still being determined. Most patients with TED develop eye manifestations while being treated for hyperthyroidism and under the care of endocrinologists. Endocrinologists, therefore, have a key role in diagnosis, initial management, and selection of patients who require referral to specialist care. Given that the need for guidance to endocrinologists charged with meeting the needs of patients with TED transcends national borders, and to maximize an international exchange of knowledge and practices, the American Thyroid Association and European Thyroid Association joined forces to produce this Consensus Statement.

DOI: 10.1530/ETJ-22-0189

read more

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Powered by

Brought to you by

Supported through an independent
educational grant by

© 2022 rareLife solutions Inc.